During the past decade, EMC Instytut Medyczny S.A. conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 7 clinical trials were completed, i.e. on average, 43.8% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 7 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "EMC Instytut Medyczny S.A." #1 sponsor was "Hoffmann-La Roche" with 8 trials, followed by "Janssen Research & Development, LLC" with 3 trials sponsored, "Genentech, Inc." with 2 trials sponsored, "University of Minnesota" with 2 trials sponsored and "Bayer" with 2 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "EMC Instytut Medyczny S.A." #1 collaborator was "National Institute of Allergy and Infectious Diseases (NIAID)" with 2 trials as a collaborator, "ANRS, Emerging Infectious Diseases" with 1 trials as a collaborator, "Abbott" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator and "Copenhagen HIV Programme (CHIP) -- Copenhagen, Denmark" with 1 trials as a collaborator. Other collaborators include 13 different institutions and companies that were collaborators in the rest 23 trials.

According to Clinical.Site data, the most researched conditions in "EMC Instytut Medyczny S.A." are "Ulcerative Colitis" (5 trials), "Chronic Rhinosinusitis" (2 trials), "Hepatitis B, Chronic" (2 trials), "Nasal Polyps" (2 trials) and "Relapsing Multiple Sclerosis" (2 trials). Many other conditions were trialed in "EMC Instytut Medyczny S.A." in a lesser frequency.

Most popular intervention types in "EMC Instytut Medyczny S.A." are "Drug" (20 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Etrolizumab" (3 trials), "JNJ-73763989" (2 trials), "Omalizumab" (2 trials) and "Tenofovir disoproxil" (2 trials). Other intervention names were less common.

The vast majority of trials in "EMC Instytut Medyczny S.A." are 21 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "EMC Instytut Medyczny S.A.". undefined are not yet recruiting, 4 are recruiting, 3 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 13 completed trials in EMC Instytut Medyczny S.A., undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in EMC Instytut Medyczny S.A., 0 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".